- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 28.02. | Nxera sells APAC license to lupus drug to Viatris for $10M upfront | ||
| 27.02. | Vir, awaiting 'functional cure' data for hep B combo, won't take treatment forward alone | ||
| 27.02. | Trump HHS re-evaluating Biden administration's $590M bird flu vaccine contract with Moderna: Bloomberg | ||
| 27.02. | Teleflex plays musical chairs, plans company split amid €760M Biotronik cardiovascular deal | ||
| 27.02. | Kallyope links oral obesity combo to 3% weight loss, rejigs pipeline as migraine asset advances | ||
| 27.02. | Vertex axes Verve gene editing pact amid shift in R&D priorities | ||
| 27.02. | Silence slows phase 3 plans for cardio drug, as Hansoh opts out of $1.3B biobucks collab | ||
| 26.02. | Health tech firm partners with UK medical recordkeeper to match patients with clinical trials | ||
| 26.02. | Wearable defibrillator maker Kestra Medical plots $150M IPO | ||
| 26.02. | Quest Diagnostics to claim Fresenius Medical Care's kidney dialysis testing portfolio | ||
| 26.02. | Alopexx seeks $11M IPO to advance ex-Sanofi infectious disease drug | ||
| 26.02. | Eikon remains in megaround mode with $350M series D to fund cancer trials | ||
| 26.02. | With no buyer for Tryvio, Idorsia claws back $100M from a double-asset deal with Viatris | ||
| 26.02. | AstraZeneca, eyeing $5B peak sales, reports phase 3 breast cancer win for oral SERD | ||
| 26.02. | Harbour offshoot pens $395M biobucks deal for preclinical rival to Neurocrine's Crenessity | ||
| 25.02. | Tandem Diabetes Care insulin-dosing algorithm nets FDA clearance for Type 2 diabetes | ||
| 25.02. | Emalex dopamine blocker stops Tourette syndrome relapse in phase 3 win | ||
| 25.02. | FDA updates Boston Scientific's Accolade pacemaker recall, reporting 832 injuries | ||
| 25.02. | Kiniksa adds to Sjögren's exodus with trial termination, axes AstraZeneca asset | ||
| 25.02. | Polish biotech Ryvu waves goodbye to 30% of staff in focus on phase 3 blood cancer trials | ||
| 25.02. | Lava, smoldering from dropping lead asset, lays off 30% of staff to save cash | ||
| 25.02. | Repare unveils scale of layoffs with 75% of staff and chief medical officer heading for exit | ||
| 25.02. | BioCity's ETA antagonist reduces proteinuria in phase 2 trial of diabetic kidney disease | ||
| 24.02. | Antibodies stop tissue damage and reduce virus levels in mice with deadly Crimean-Congo hemorrhagic fever | ||
| 24.02. | Regeneron gene therapy improves hearing in 10 children with rare form of hearing loss |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
